GLP1R and metabolic dysfunction-associated steatotic liver disease: Altogether, these studies illustrate that GLP-1 receptor agonists like semaglutide consistently improve steatosis, metabolic markers, and liver enzymes in MASLD, although effects on fibrosis may be more limited, particularly in advanced disease stages.